Chuck Oneill
Co-founder, CEO and Chair of the Board of Directors @Osod, A Merit Company
Signup · Get unlimited contacts
WORK HISTORY
Co-founder, CEO and Chair of the Board of Directors @Osod, A Merit Company
Park City, UT, US
MCAL Therapeutics is a biotechnology company developing a new class of synthetic lipid therapies to treat evaporative dry eye and related ophthalmic conditions. Inspired by nature and built for durability, MCAL’s therapies are designed to support the eye’s natural moisture barrier, stabilize the tear film, and offer lasting symptom relief. MCAL’s lead program, MCAL 201, for evaporative dry eye disease is expected to enter the clinic in 2026.
EDUCATION
University of Redlands
B.S., Biology
University of California, Davis
Ph.D., Pharmacology and Toxicology
ABOUT CHUCK ONEILL
I am an ophthalmology-focused biotech leader with a 30-year track record of translating…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.